ATRM (ATRM) Stock Price, News & Analysis

Company Overview

Atretium Therapeutics, Inc. (OTCMKTS: ATRM) is a biotechnology company focused on the development and commercialization of regenerative cell therapies for cartilage repair and osteoarthritis. Originally founded under the name Nexgel in 2013, the company rebranded to Atretium Therapeutics to better reflect its dedication to advancing tissue regeneration technologies. Atretium’s platforms leverage proprietary cell composition techniques designed to promote natural healing of degraded joint tissue and to provide long-term pain relief for patients suffering from degenerative joint disorders.

The company’s lead product candidate, ARTCELL, is a cell-based injectable therapy aimed at slowing or reversing cartilage damage in knee osteoarthritis. ARTCELL is formulated to stimulate local regeneration of joint tissue through a minimally invasive injection procedure. In addition to ARTCELL, Atretium is advancing a pipeline of follow-on therapies that target larger joint surfaces and more advanced stages of degeneration, utilizing similar cell processing methods to enhance tissue repair and functional recovery.

Atretium has established strategic partnerships to support its clinical development and commercialization efforts, most notably a joint venture in the Asia-Pacific region that enables access to regulatory pathways and distribution networks across Japan and neighboring markets. The company’s clinical programs have been structured to meet both U.S. Food and Drug Administration and international regulatory requirements, with trials designed to assess safety, efficacy and patient-reported outcomes. Atretium’s manufacturing operations are conducted in compliance with current Good Manufacturing Practice (cGMP) standards, ensuring consistent product quality for both domestic and overseas patients.

Headquartered in Florida, Atretium is led by a management team and board of directors with extensive experience in biotechnology, cell therapy development and pharmaceutical commercialization. The leadership group brings together veterans from the regenerative medicine sector, clinical research and regulatory affairs to navigate complex clinical pathways and forge collaborations with healthcare providers. Through its commitment to innovation and rigorous clinical investigation, Atretium aims to redefine the treatment paradigm for orthopedic disorders and improve quality of life for patients worldwide.

Key Stats

• Today's Range: $0.22 to $0.22
• 50-Day Range: $0.22 to $0.22
• 52-Week Range: $0.10 to $0.65
• Volume: N/A
• Average Volume: 5,948 shs
• Market Capitalization: $555.72 thousand
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

ATRM Stock Analysis - Frequently Asked Questions

How have ATRM shares performed this year?

ATRM's stock was trading at $0.22 at the start of the year. Since then, ATRM stock has increased by 0.0% and is now trading at $0.22.

How do I buy shares of ATRM?

Shares of ATRM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of ATRM own?

Based on aggregate information from My MarketBeat watchlists, some other companies that ATRM investors own include Atkore (ATKR), Ashtead Group (ASHTY), Arconic (ARNC), Aperam (APEMY), Advanced Micro Devices (AMD), Achaogen (AKAO) and Agritek (AGTK).

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Construction
• Industry: Prefabricated Wood Buildings
• Sub-Industry: Construction Materials
• Current Symbol: OTCMKTS:ATRM
• CIK: 908598
• Web: www.atrmholdings.com
• Phone: 651-704-1800
• Fax: N/A
• Employees: 140
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$3.52 million
• Net Margins: -13.14%
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: -35.32%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.29
• Quick Ratio: 0.20

Sales & Book Value

• Annual Sales: $34.48 million
• Price / Sales: 0.02
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($3.77) per share
• Price / Book: -0.06

Miscellaneous

• Outstanding Shares: 2,526,000
• Free Float: N/A
• Market Cap: $555.72 thousand
• Optionable: Not Optionable
• Beta: -0.90